Oncology
Brain Glioma
7
Pipeline Programs↗
3
Active Trials↗
5
Companies Involved↗
Brain Glioma is an early-stage landscape with 7 programs across 5 companies. The most active players are Hebei Senlang Biotechnology Inc., Ltd., Essen Biotech, Bayer. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Approved
No programs
Analysis
Modality Breakdown
6programs
Small molecule350%
Cell therapy233%
Monoclonal antibody117%
Modality classified for 100% of 7 pipeline programs.
Analysis
Trial Status
6
clinical trials
Recruiting3 · 50%
Completed2 · 33%
Withdrawn1 · 17%
Clinical Trials
Trial Activity
6 trials
Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection
Recruiting·—·Phase 1/2·NCT06018363·25 enrolled
C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression
Withdrawn·—·Phase 2/3·NCT01961934
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)